After many years in the oncology industry, and too many years as a caregiver, I’ve witnessed the dramatic changes in breast cancer treatments. Targeted therapies, antibody-drug conjugates, endocrine therapies, CDK4/6 inhibitors and immunotherapies have given many patients more options—and, in some cases, substantially more time.
But metastatic breast cancer remains a formidable challenge. For breast cancer patinets with metastaces, treatment is generally not considered curative. The goal is often to control the disease, extend survival and preserve quality of life. And when a treatment stops working, patients and their physicians must move to another option.
That creates a fundamental unmet need:
What happens when the available treatments run out?
The answer is particularly difficult for patients with aggressive disease or tumors that develop resistance to multiple therapies. Metastatic triple-negative breast cancer, for example, continues to have less favorable survival outcomes than some other metastatic breast cancer subtypes.
And resistance isn’t simply a matter of finding another drug. Cancer evolves.
A tumor that initially responds to treatment can change biologically, evade the immune system or develop mechanisms that allow it to survive increasingly sophisticated therapies. Recent research presented at #ASCO26 continues to identify genomic markers associated with resistance to first-line therapy in hormone receptor-positive metastatic breast cancer.
This raises a bigger question for drug innovators:
Do we need more iterations of existing approaches—or fundamentally different ways of engaging cancer?
Immunotherapy offers one possible path, but breast cancer has proven challenging terrain for immuno-oncology. The success seen with immune checkpoint inhibitors in some cancers has not translated uniformly across breast cancer.
That is why the next generation of research is so important.
Researchers are exploring approaches designed to make cancer more visible to the immune system, stimulate stronger antitumor immune responses, target specific vulnerabilities within cancer cells and combine different mechanisms to overcome resistance.
Cellular immunotherapy is one of those emerging approaches.
The idea is compelling: rather than relying solely on a drug to directly kill cancer cells, can we harness—or better direct—the patient’s own immune system to recognize and attack cancer? The challenge is turning that biological promise into treatments that are effective, safe, scalable and accessible.
The future of cancer therapy cannot simply be about discovering something that works in a laboratory. New treatments must ultimately be capable of reaching the patients who need them, fitting into real-world clinical practice and improving outcomes without imposing an unacceptable burden.
There is hope. Clinical research continues to expand the therapeutic toolbox for metastatic breast cancer, including new combinations, targeted therapies, antibody-drug conjugates and immunotherapy approaches. Recent ASCO data, for example, demonstrated continued progress in treatment strategies for metastatic triple-negative breast cancer—while also underscoring how urgently better outcomes are still needed.
But progress shouldn’t obscure the remaining challenge. For someone living with metastatic breast cancer, “more options” is not the same as a cure. The ultimate goal should be to make metastatic breast cancer increasingly controllable, increasingly treatable—and, eventually, no longer synonymous with an incurable disease.
That will require more than incremental advances. It will require new thinking, new biology and new approaches to treatment. And that’s why the unmet need in metastatic breast cancer remains one of the most important challenges in oncology today.
Patients and family can find support and education at CancerCare (https://www.cancercare.org/), Susan G. Komen Breast Cancer Foundation (https://www.komen.org/), and Living Beyond Breast Cancer east Cancer (https://www.lbbc.org/).